A new study reveals that AI models behind chatbots, Grok 4.7 and GPT-6.1 Sol, show significant political bias when asked to pick candidates in the 2024 US midterm elections. Grok favored Republican candidates 92% of the time, while GPT chose Democrats 97% of the time, agreeing in less than 10% of races. These biases stem from differences in the sources and topics each model prioritizes, with Grok focusing on conservative sources and issues like immigration and taxes, and GPT leaning on more liberal topics such as healthcare and abortion. The study highlights concerns about hidden biases in AI that could influence voter information, especially as only 8% of Americans use chatbots for election info. The findings raise important questions about AI neutrality and the impact of underlying data and search patterns on political recommendations.
The AI models' political bias in the 2024 US midterm elections is striking, with Grok favoring Republicans 92% of the time and GPT choosing Democrats 97% of the time. For readers following the Technology sector, here is Pluang's market snapshot as of Oct 24, 2026 19:11 WIB: out of 150 priced US tech stocks, 82 rose and 65 fell. Notable movers include Fastly Inc (FSLY) at USD 24.41 with a 1-day change of +8.73% and a typical hold time of 26 days, Crowdstrike Holdings Inc (CRWD) at USD 257.57 with +8.25% change and 98 days hold time, and Zscaler Inc (ZS) at USD 255.15 with +7.31% change and 42 days hold time.
The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...
XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...
XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
